Boutique Biotech $20 / month

Boutique Biotech, authored by a University of Chicago faculty member, provides analytical insights into the biotech stock market, focusing on company spotlights, acquisition news, market trends, and educational content on biotech investing. It evaluates FDA approvals, clinical trial data, and financial strategies within the sector.

Biotech Investment Strategies Clinical Trial Data Interpretation FDA Approval Processes Biotech Company Spotlights Market Trends and Analysis Biotech Educational Content Obesity Treatment Developments Medical Devices

Structure Therapeutics in the spotlight

19 implied HN points • 29 Sep 23

🔬 Science Pharmaceuticals Biotech

Structure Therapeutics' GPCR showed significant weight reduction in overweight patients with their oral GLP-1 receptor agonist GSBR-1290.
The once-a-day pill resulted in 4.8kg weight loss, approximately 5.4% at the highest dose after 28 days.
The data from Structure Therapeutics' Phase 1b study is compared with other oral medications for obesity in the same field.

Biotech Basics: Charts

19 implied HN points • 30 Aug 23

🔬 Science Biotech Investing Charts

Educational content for understanding biotech investing through charts.
Biotechs often use various types of graphs to represent data outcomes.
Knowing and understanding important plots in biotech can be crucial when interpreting data.

Happy holidays from Boutique Biotech!

19 implied HN points • 26 Dec 23

🔬 Science Biotech M&A Pharmaceuticals Neuroscience FDA

Bristol Myers Squibb acquired Karuna Therapeutics for $14B, expanding their pipeline.
Karuna's lead asset is currently under FDA review with a PDUFA date set for Sept. 26, 2024.
The post is exclusive for paid subscribers of Boutique Biotech.

PDS Biotechnology in the spotlight

0 implied HN points • 13 Jun 23

💰 Finance Biotechnology

PDS Biotechnology faced a drop in stock value after uncertainty surrounding response rates.
The company reported a 41.2% confirmed/unconfirmed overall response rate.
Consider the buy opportunity with PDS Biotechnology or watch from the sidelines.

Biotech Basics: Medical Devices

0 implied HN points • 16 Jul 23

🏥 Health & Wellness Biotech Medical Devices

FDA approval process for medical devices is different from prescription drugs
Understanding FDA's medical device classification is important for stock market understanding
Discussion on hundreds of public companies commercializing their own medical devices

Get a weekly roundup of the best Substack posts, by hacker news affinity:

Gossamer Bio in the spotlight (part III)

0 implied HN points • 01 Aug 23

💰 Finance Biotech Investing

Gossamer Bio discussed Phase 2 results, OLE data, and Phase 3 design in a KOL call.
Some PAH patients reached a "normalized" level in the OLE continued seralutinib group.
The post is for paid subscribers only.

Modular Medical in the spotlight

0 implied HN points • 22 Jan 24

💰 Finance Healthcare FDA Approval

Modular Medical submitted their MODD1 insulin pump for FDA approval.
FDA approval timeline can vary from 6 to 9 months for medical devices.
This post is for paid subscribers only.

Biotech Basics: Avoiding Common Pitfalls

0 implied HN points • 15 Jun 23

💰 Finance Biotech Investing

Biotech stock trading down after announcing 'successful results' could indicate data not being truly successful.
Companies may highlight cherry-picked positive results, while the overall study did not meet expectations.
It's important to be cautious when biotech companies start discussing specific parts of their studies.

Obesity in the spotlight (part II)

0 implied HN points • 26 Jun 23

🏥 Health & Wellness Obesity Diabetes Pharmaceuticals

Latest updates on oral obesity treatments at ADA conference
Trend towards developing oral GLP-1 drugs for obesity
Focus on challenging big pharma with innovative obesity treatments

Gossamer Bio in the spotlight

0 implied HN points • 21 Jun 23

💰 Finance Stocks Biotech Investing Pharmaceuticals

Gossamer Bio's stock fell in December 2022 after Phase 2 data release.
GOSS performed well in 'sicker' Class III PAH patients but not as well in 'less sick' Class II patients.
The post discusses a deep dive into the value and outlook of Gossamer Bio.

Pfizer in the spotlight

0 implied HN points • 22 May 23

🏥 Health & Wellness Weight Loss Drug Development

Biotech industry is rebounding despite FTC news affecting M&A activity last week.
Weight loss sector is gaining attention with Pfizer's oral GLP-1 drug in spotlight.
Pfizer's data on weight loss drug was published in JAMA, creating buzz in the market.